Effects of mecasermin injection: A Synthesis of Findings from 10 Studies

  1. Home
  2. Effects of mecasermin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of mecasermin injection: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of mecasermin injection: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Mecasermin is a drug developed to treat growth disorders such as growth hormone insensitivity syndrome (Laron syndrome) and insulin resistance. 5 , 8 , 9 , 7 , 6 , 4 Mecasermin promotes growth by stimulating the production of insulin-like growth factor 1 (IGF-1), which assists in the function of growth hormone. 5 , 6 However, a study on children with Laron syndrome showed that although mecasermin treatment improved growth, growth failure remained severe. 5 Mecasermin has also been shown to be effective in treating insulin resistance. 8 , 6 Studies on diabetic patients with insulin resistance have reported that mecasermin improves insulin sensitivity and glycemic control. 8 Mecasermin is also promising as a potential treatment for spinal muscular atrophy (SMA). 10 In SMA mouse models, mecasermin has shown improvements in motor performance, reduced weight loss, and increased survival. 10 On the other hand, mecasermin has the potential to cause side effects such as hypoglycemia, headache, and intracranial hypertension. 5 Animal studies have also reported hypertrophy of other organs (kidneys, spleen, and heart) as well as carcinogenic effects. The risk to humans is unknown. 5 The mecasermin packaging is not well-suited (a multi-dose vial designed for multiple punctures), posing a potential source of contamination and errors. Prefilled pens or syringes would be easier to use. 5

Benefits and Risks

Benefits Summary

Mecasermin shows promise as a treatment for growth disorders such as growth hormone insensitivity syndrome (Laron syndrome) and insulin resistance. 5 , 8 , 9 , 7 , 6 A study on children with Laron syndrome showed mecasermin helped improve growth. 5 In diabetic patients with insulin resistance, mecasermin improved insulin sensitivity and glycemic control. 8 Mecasermin is also promising as a potential treatment for spinal muscular atrophy (SMA). 10 In SMA mouse models, mecasermin has shown improvements in motor performance, reduced weight loss, and increased survival. 10

Risks Summary

Mecasermin has the potential to cause side effects such as hypoglycemia, headache, and intracranial hypertension. 5 Animal studies have also reported hypertrophy of other organs (kidneys, spleen, and heart) as well as carcinogenic effects. The risk to humans is unknown. 5 The mecasermin packaging is not well-suited (a multi-dose vial designed for multiple punctures), posing a potential source of contamination and errors. Prefilled pens or syringes would be easier to use. 5

Research Comparisons

Research Commonalities

Mecasermin is a promising drug for treating growth disorders such as growth hormone insensitivity syndrome (Laron syndrome) and insulin resistance. 5 , 8 , 9 , 7 , 6 , 4 Mecasermin promotes growth by stimulating the production of insulin-like growth factor 1 (IGF-1), which assists in the function of growth hormone. 5 , 6 Mecasermin is also shown to be effective in treating insulin resistance. 8 , 6

Research Differences

The effectiveness of mecasermin varies depending on the targeted disease and the research design. A study on children with Laron syndrome showed that although mecasermin treatment improved growth, growth failure remained severe. 5 In diabetic patients with insulin resistance, mecasermin improved insulin sensitivity and glycemic control. 8 Mecasermin is also promising as a potential treatment for spinal muscular atrophy (SMA). 10 In SMA mouse models, mecasermin has shown improvements in motor performance, reduced weight loss, and increased survival. 10

Consistency and Contradictions in Findings

Mecasermin shows potential for treating growth disorders and insulin resistance, but its effectiveness can vary based on the targeted disease and research design. Further research is required to more clearly assess the effectiveness of mecasermin.

Practical Application Considerations

Mecasermin is developed as a treatment for growth disorders and insulin resistance, but it has the potential to cause side effects such as hypoglycemia, headache, and intracranial hypertension. 5 When using mecasermin, it is crucial to discuss the risks and benefits of these side effects with your doctor.

Limitations of Current Research

Research on mecasermin is still limited. In particular, long-term studies on humans are lacking, and further research is needed to determine the long-term safety and effectiveness of mecasermin.

Future Research Directions

Mecasermin holds promise as a treatment for various diseases including growth disorders and insulin resistance. Large-scale clinical trials on humans are needed to further assess the effectiveness and safety of mecasermin. Additional research is also required on the dosage, administration method, and optimal treatment duration for mecasermin.

Conclusion

Mecasermin is a promising treatment option for growth disorders and insulin resistance. However, it has the potential to cause side effects such as hypoglycemia, headache, and intracranial hypertension. 5 It is essential to consult with your doctor to discuss the risks and benefits of these side effects before using mecasermin. Further research is needed to more clearly evaluate the effectiveness of mecasermin.

Literature analysis of 10 papers
Positive Content
9
Neutral Content
0
Negative Content
1
Article Type
2
0
0
5
10
1.

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Author: FunderburgNicholas, KalinowskaMagdalena, EasonJames, GoodrichJames, HeeraJayvant, MayerHoward, RajicicNatasa, ValdezHernan, LedermanMichael M

Increased CD4 count

This study examined whether maraviroc treatment for HIV-1 infection leads to larger CD4(+) T cell rises than its antiviral activity alone. Maraviroc treatment resulted in more rapid decreases in certain markers of immune activation and inflammation than efavirenz. These decreases were correlated with increased CD4(+) T cell gains.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.

Author: ChanEllen S, LandayAlan L, BrownTodd T, RibaudoHeather J, MirmonsefParia, OfotokunIgho, WeitzmannM Neale, MartinsonJeffrey, KlingmanKarin L, EronJoseph J, FichtenbaumCarl J, PlantsJill, TaiwoBabafemi O

HIV treatment

This study aimed to determine whether maraviroc (MVC) has differential immunologic effects compared with tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Mecasermin in Insulin Receptor-Related Severe Insulin Resistance Syndromes: Case Report and Review of the Literature.

Author: PlamperMichaela, GohlkeBettina, SchreinerFelix, WoelfleJoachim

Improved metabolic control
Increased lifespan
Respiratory infection

This case report discusses the treatment of a patient with Donohue syndrome using rhIGF-I.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Cardiac examination in children with Laron syndrome undergoing mecasermin therapy.

Author: ErolNurdan, YıldızMetin, GüvenAyla, YıldırımAyse

Laron syndrome treatment

This study aims to research cardiac findings of children with Laron syndrome (LS), who receive treatment with mecasermin.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Mecasermin (recombinant human insulin-like growth factor I).

Author: RosenbloomArlan L

Growth hormone insensitivity treatment
Insulin sensitization
Body fat accumulation
Cancer risk
Hypoglycemia
Lymphoid tissue hyperplasia

Recombinant human IGF-I is a medication that mimics the effects of growth hormone. It is used to treat rare conditions where the body does not respond properly to growth hormone. Although IGF-I may help with insulin resistance, there are concerns about potential side effects such as retinopathy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.

Author: WilliamsRachel M, McDonaldAnna, O'SavageMartin, DungerDavid B

Prolonged half-life
Reduced side effects

This study reviewed the use of mecasermin rinfabate (iPLEX), a complex of rhIGF-I and rhIGFBP-3, for treating growth and endocrine disorders. iPLEX was developed to prolong IGF-I half-life and potentially reduce side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.

Author:

Growth hormone insensitivity syndrome treatment
IGF-I deficiency treatment
Osteoporosis treatment

This paper discusses the development of mecasermin rinfabate, a recombinant complex of insulin-like growth factor-I (rhIGF-I) and binding protein-3 (rhIGFBP-3), for a number of metabolic and endocrine indications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.

Author: RinaldiCarlo, BottLaura C, ChenKe-lian, HarmisonGeorge G, KatsunoMasahisa, SobueGen, PennutoMaria, FischbeckKenneth H

Attenuated weight loss
Improved motor performance
Increased survival

This study investigates the use of recombinant human IGF-1 in a mouse model of spinal and bulbar muscular atrophy, a motor neuron disease. The results show that IGF-1 treatment improves motor performance, reduces weight loss, and increases survival, suggesting its potential as a treatment for this disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.